Literature DB >> 2807549

Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi.

S C Szu1, X R Li, R Schneerson, J H Vickers, D Bryla, J B Robbins.   

Abstract

The effect of molecular weight or size of the components on the immunogenicity of polysaccharide-protein conjugates prepared with the native Vi capsular polysaccharide (Vi) (approximately 3 x 10(3) kilodaltons) or lower-molecular-weight Vi (Vis; approximately 46 kilodaltons) abound to cholera toxin (CT) or to its B subunit (CTB) was studied. In mice, Vi-CT, Vi-CTB, and Vis-CTB elicited higher Vi antibody levels than the Vi alone (P less than 0.0001). Vi-CT and Vi-CTB were more immunogenic than Vis-CTB (P less than 0.01). CT or Vi-CT elicited higher levels of CT antibodies, as measured by enzyme-linked immunosorbent assay, than did CTB or Vi-CTB. In rhesus monkeys, the Vi conjugates elicited higher Vi antibody levels than the Vi alone (P less than 0.01). Vi-CTB elicited higher levels of Vi antibody after each injection than did Vis-CTB. Similar levels of CT antibodies, as measured by enzyme-linked immunosorbent assay, were elicited by all three conjugates. In contrast, Vi-CT elicited higher levels of neutralizing antibodies than Vi-CTB or Vis-CTB when either CT or the related heat-labile toxin of Escherichia coli was used as the antigen. These results indicate that the holotoxin and the native Vi provide the most immunogenic components for conjugates designed to induce both Vi and CT antibodies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2807549      PMCID: PMC259911          DOI: 10.1128/iai.57.12.3823-3827.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  Application of optical properties of the Vi capsular polysaccharide for quantitation of the Vi antigen in vaccines for typhoid fever.

Authors:  A L Stone; S C Szu
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

2.  Rabbit antibodies to the cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal challenge with encapsulated pneumococci.

Authors:  S C Szu; R Schneerson; J B Robbins
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

3.  Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines.

Authors:  C O Tacket; C Ferreccio; J B Robbins; C M Tsai; D Schulz; M Cadoz; A Goudeau; M M Levine
Journal:  J Infect Dis       Date:  1986-08       Impact factor: 5.226

4.  Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.

Authors:  K P Klugman; I T Gilbertson; H J Koornhof; J B Robbins; R Schneerson; D Schulz; M Cadoz; J Armand
Journal:  Lancet       Date:  1987-11-21       Impact factor: 79.321

5.  Ultrasonic irradiation of bacterial polysaccharides. Characterization of the depolymerized products and some applications of the process.

Authors:  S C Szu; G Zon; R Schneerson; J B Robbins
Journal:  Carbohydr Res       Date:  1986-09-01       Impact factor: 2.104

6.  Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report.

Authors:  I L Acharya; C U Lowe; R Thapa; V L Gurubacharya; M B Shrestha; M Cadoz; D Schulz; J Armand; D A Bryla; B Trollfors
Journal:  N Engl J Med       Date:  1987-10-29       Impact factor: 91.245

7.  Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals.

Authors:  S C Szu; A L Stone; J D Robbins; R Schneerson; J B Robbins
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

8.  Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugates.

Authors:  A Fattom; W F Vann; S C Szu; A Sutton; X Li; D Bryla; G Schiffman; J B Robbins; R Schneerson
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

9.  Epitopes of the cholera family of enterotoxins.

Authors:  R A Finkelstein; M F Burks; A Zupan; W S Dallas; C O Jacob; D S Ludwig
Journal:  Rev Infect Dis       Date:  1987 May-Jun

Review 10.  Bacterial protein toxins with latent ADP-ribosyl transferases activities.

Authors:  C Y Lai
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1986
View more
  38 in total

1.  Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1.

Authors:  V Pozsgay; C Chu; L Pannell; J Wolfe; J B Robbins; R Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls.

Authors:  E Konadu; J Shiloach; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

3.  Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin.

Authors:  R K Gupta; S C Szu; R A Finkelstein; J B Robbins
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

4.  Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.

Authors:  Changfa Cui; Rodney Carbis; So Jung An; Hyun Jang; Cecil Czerkinsky; Shousun C Szu; John D Clemens
Journal:  Clin Vaccine Immunol       Date:  2009-11-04

5.  Synthesis and immunogenicity evaluation of Salmonella enterica serovar Paratyphi A O-specific polysaccharide conjugated to diphtheria toxoid.

Authors:  Aamir Ali; So J An; Changfa Cui; Abdul Haque; Rodney Carbis
Journal:  Hum Vaccin Immunother       Date:  2014-03-06       Impact factor: 3.452

6.  Characterization of a human monoclonal immunoglobulin M (IgM) antibody (IgMBEN) specific for Vi capsular polysaccharide of Salmonella typhi.

Authors:  J Liao; K G Nickerson; S Bystricky; J B Robbins; R Schneerson; S C Szu; E A Kabat
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

7.  Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis.

Authors:  T G Blanchard; N Lycke; S J Czinn; J G Nedrud
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

8.  Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice.

Authors:  Zhigang Jin; Chiayung Chu; John B Robbins; Rachel Schneerson
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

9.  A Study on Longevity of Immune Response after Vaccination with Salmonella Typhi Vi Conjugate Vaccine (Pedatyph™) in Children.

Authors:  Balaji Chinnasami; Kanimozhi Sadasivam; Aravindhan Vivekanandhan; Prema Arunachalam; Sekar Pasupathy
Journal:  J Clin Diagn Res       Date:  2015-05-01

10.  Relation between structure and immunologic properties of the Vi capsular polysaccharide.

Authors:  S C Szu; X R Li; A L Stone; J B Robbins
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.